There was a striking reduction in the leukemia burden in the liver, spleen, and BM of mice treated with CD123-ENG or CD123-ENG.IL15 T-cells compared to mice that had received NT or CD19-ENG.IL15 T-cells (Figures 3F, G; S5). This evidence concerns the gene CD19 and leukemia.